Your browser doesn't support javascript.
loading
Regorafenib (BAY 73-4506): stromal and oncogenic multikinase inhibitor with potential activity in renal cell carcinoma.
Zaki, Kamarul; Aslam, Shahzeena; Eisen, Tim.
Afiliación
  • Zaki K; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. Kamarul.Zaki@addenbrookes.nhs.uk
Curr Oncol Rep ; 15(2): 91-7, 2013 Apr.
Article en En | MEDLINE | ID: mdl-23334510
The introduction of targeted therapies, specifically those that target the VEGF receptor (VEGFR), PDGF receptor (PDGFR) and the mTOR pathways, has significantly changed the approach to patients with unresectable renal cell cancer (RCC). However, drug resistance develops through bypassing of targeted pathways. Regorafenib (BAY 73-4506) is a novel bi-aryl urea compound that has potential anti-tumour activity in RCC, as along with targeting VEGF and PDGF receptors, it targets additional kinases associated with alternative pathways of angiogenesis and resistance to VEGF-targeted drugs. Based on a phase II clinical trial, the efficacy outcome of regorafenib in the first-line setting of unresectable RCC appears comparable that of other targeted first-line drugs. However, testing regorafenib in standard phase III trials seems inappropriate in view of its toxic effects. Further assessment of regorafenib should exploit the drug's ability to inhibit mechanisms of escape from anti-angiogenic treatment through biomarker-driven clinical trials.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos de Fenilurea / Piridinas / Carcinoma de Células Renales / Inhibidores de la Angiogénesis / Inhibidores de Proteínas Quinasas / Neoplasias Renales / Antineoplásicos Límite: Humans Idioma: En Revista: Curr Oncol Rep Asunto de la revista: NEOPLASIAS Año: 2013 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos de Fenilurea / Piridinas / Carcinoma de Células Renales / Inhibidores de la Angiogénesis / Inhibidores de Proteínas Quinasas / Neoplasias Renales / Antineoplásicos Límite: Humans Idioma: En Revista: Curr Oncol Rep Asunto de la revista: NEOPLASIAS Año: 2013 Tipo del documento: Article Pais de publicación: Estados Unidos